Concepedia

Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure

Michael Böhm, Stefan D. Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Stuart Pocock, Felix Mahfoud, Martina Brueckmann, Waheed Jamal, Anne Pernille Ofstad,

Journal of the American College of Cardiology · 2021 · 84 citations · 22 references

DOIFull text

Open access

Abstract

Empagliflozin was effective and safe, with no meaningful interaction between SBP and the effects of empagliflozin in the EMPEROR-Reduced trial. (Empagliflozin Outcome Trial in Patients With Chronic Heart Failure With Reduced Ejection Fraction [EMPEROR-Reduced]; NCT03057977).

References

22

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

John J.V. McMurray, Scott D. Solomon, Silvio E. Inzucchi et al. · New England Journal of Medicine · 2019 · 6.4K citations · Full text

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer, Stefan D. Anker, Javed Butler et al. · New England Journal of Medicine · 2020 · 4.7K citations · Full text

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

John J.V. McMurray, Jan Östergren, Karl Swedberg et al. · The Lancet · 2003 · 2.6K citations

, , +10

Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure

Milton Packer, Michael B. Fowler, Ellen B. Roecker et al. · Circulation · 2002 · 1.3K citations

CHARM IN-VESTIGATORS AND COMMITTEES. EFFECTS OF CANDESARTAN IN PATIENTS WITH CHRONIC HEART FAILURE AND REDUCED LEFT-VENTRICULAR SYSTOLIC FUNCTION TAKING ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS: THE CHARM-ADDED TRIAL

John J.V. McMurray, Jan Östergren, Karl Swedberg et al. · The Lancet · 2003 · 1K citations

, , +6